


PHARMACEUTICAL 2021



PUMA BIOTECHNOLOGY INC. Rank 187 of 409





PHARMACEUTICAL 2021



PUMA BIOTECHNOLOGY INC. Rank 187 of 409

The relative strengths and weaknesses of PUMA BIOTECHNOLOGY INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA BIOTECHNOLOGY INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 306% points. The greatest weakness of PUMA BIOTECHNOLOGY INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -101%, being 253% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	146,139
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	114,255
Liabilities, Non-Current	103,574
Other Assets	95,600
Other Compr. Net Income	-62
Other Expenses	39,581
Other Liabilities	32,342
Other Net Income	-29,386
Property and Equipment	2,481
Research and Development	97,650
Revenues	225,110
Selling, General and Administrative Expense	118,488

Output Variable	Value in 1000 USD
Assets	244,220
Liabilities	250,171
Expenses	255,719
Stockholders Equity	-5,951
Net Income	-59,995
Comprehensive Net Income	-60,026
Economic Capital Ratio	-101%